EUVIMEDEUVIMED entdecken
Crossref

MEF2C promoter variants in patent ductus arteriosus: a genetic and functional study

Shao-Jie Wang iD, Huan-Xin Chen iD, Qin Yang iD, Guo-Wei He iD

Human Molecular Genetics · 25.09.2026 · 35 (20)

DOI: 10.1093/hmg/ddag097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, online erschienen am 26.09.2026. Verfasst von Shao-Jie Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery & The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin University, No. …. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Promoter Regions, Genetic, MEF2 Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Internal Fund from TEDA International Cardiovascular Hospital, Tianjin Key Medical Discipline Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patent ductus arteriosus (PDA) is a common congenital heart disease (CHD) with a complex genetic basis. The transcription factor MEF2C plays a critical role in cardiac development, but the role of promoter region variants in PDA has not been explored. This study aimed to identify MEF2C promoter variants in PDA patients and investigate their functional consequences. We sequenced the MEF2C promoter region in 318 children with PDA and 306 healthy controls. Identified variants were subjected to dual-luciferase reporter assays in A7r5 vascular smooth muscle cells to assess transcriptional activity. Bioinformatics (JASPAR) and electrophoretic mobility shift assays (EMSA) were used to predict and validate changes in transcription factor binding. Seventeen variants were identified, of which seven were present exclusively in PDA patients. Three variants were novel. Dual-luciferase assays showed that six variants significantly altered promoter activity compared to wild-type (range 69.6%–82.3%). JASPAR prediction revealed that these variants affected binding sites for 16 transcription factors, including GATA1, GATA2, GATA3, STAT3, ZEB1 and E2F1. EMSA confirmed altered DNA-protein binding patterns for all six variants, and super-shift assays further validated that the g.24571 A > G variant specifically disrupts GATA3 binding. This is the first study to identify functionally relevant MEF2C promoter variants in PDA. Our findings suggest that dysregulation of MEF2C through promoter variants may contribute to PDA pathogenesis by disrupting critical transcription factor interactions. These results extend the genetic landscape of PDA beyond coding regions and provide new insights into the molecular mechanisms of CHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ductus Arteriosus, PatentPromoter Regions, GeneticMEF2 Transcription FactorsHumansFemaleMaleBinding SitesInfantChildChild, PreschoolProtein Binding

Stichwörter der Autor:innen

MEF2C genecongenital heart diseasepatent ductus arteriosus

Substanzen

MEF2 Transcription FactorsMEF2C protein, human

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery & The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin University, No. 61, 3rd Ave, TEDA, Tianjin 300457, China.
  • Graduate School, Chengde Medical University, Anyuan Road, Shuangqiao District, Chengde 067000, China.
  • Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine, No. 61, 3rd Ave, TEDA, Tianjin 300457, China.
  • TEDA International Cardiovascular Hospital, Chinese Academy of Medical Sciences, No. 61, 3rd Ave, TEDA, Tianjin 300457, China.

ORCID-Profile: Shao-Jie Wang, Huan-Xin Chen, Qin Yang, Guo-Wei He

Förderung

  • National Natural Science Foundation of China
  • Internal Fund from TEDA International Cardiovascular Hospital
  • Tianjin Key Medical Discipline Construction Project
  • Special Fund for High Quality Development Project

Zitieren

APA

Wang, S. J., Chen, H. X., Yang, Q., & He, G. W. (2026). MEF2C promoter variants in patent ductus arteriosus: a genetic and functional study. Human Molecular Genetics, 35(20). https://doi.org/10.1093/hmg/ddag097

Vancouver

Wang SJ, Chen HX, Yang Q, He GW. MEF2C promoter variants in patent ductus arteriosus: a genetic and functional study. Human Molecular Genetics. 2026;35(20). doi:10.1093/hmg/ddag097

BibTeX
@article{Wang2026,
  author = {Wang, Shao-Jie and Chen, Huan-Xin and Yang, Qin and He, Guo-Wei},
  title = {MEF2C promoter variants in patent ductus arteriosus: a genetic and functional study},
  journal = {Human Molecular Genetics},
  year = {2026},
  volume = {35},
  number = {20},
  doi = {10.1093/hmg/ddag097}
}
Kostenlos starten →